PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION
This article was originally published in The Gold Sheet
...is driving pharmaceutical manufacturers to realign their organizational structures to handle the cross-functional demands involved. Biogen Idec and Sanofi-Aventis are among those firms who have developed integrative team approaches to building the momentum needed for bringing the projects to fruition. Close communication with FDA is proving to be an important support mechanism for working through the many challenges. Like FDA, the EU’s EMEA also has put a PAT initiative in place to help facilitate implementation. Although the attention has been on big pharma, firms whose lifeblood is efficiency such as generic product and contract manufacturers may become PAT pathfinders. [A presentation by Sanofi-Aventis’ Fischer on his firm’s groundbreaking PAT pilot project and comparability protocol is included. Also included are discussions by Xcellerex’s Galliher on PAT in biomanufacturing’s future and by Pfizer’s Migliaccio on the evolution of manufacturing science and PAT applications]
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.